Loading...
Loading...
Analysts at Nomura downgraded
Pharmacyclics Inc. PCYC from Buy to Neutral.
The price target for Pharmacyclics has been raised from $196 to $261.25.
Pharmacyclics shares have climbed 93.26% over the past 52 weeks, while the S&P 500 index has gained 11.87% in the same period.
Pharmacyclics' shares climbed 10.30% to close at $254.22 yesterday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in